Keeping RelApse in Chk: molecular mechanisms of Chk1 inhibitor resistance in lymphoma
Open Access
- 23 November 2022
- journal article
- editorial
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 479 (22), 2345-2349
- https://doi.org/10.1042/bcj20220461
Abstract
Chk1 is a member of the DNA damage response pathway, whose loss leads to replication stress and genome instability. Because of its protective role against lethal levels of DNA replication stress, Chk1 has been studied as a valuable and intriguing target for cancer therapy. However, one of the most prominent challenges with this strategy is development of resistance to Chk1 inhibitors, rendering the treatment ineffective. In their recent papers, Hunter and colleagues demonstrate multiple mechanisms by which Chk1 inhibitor resistance can arise in lymphomas. Specifically, this series of papers identify the relationship between dysfunction in NF-κB and the development of Chk1 inhibitor resistance through a loss of Chk1 activity in mouse models of lymphoma. They identify that cells lacking Chk1 activity can compensate for this loss through up-regulation of alternative pathways, such as PI3K/AKT. Finally, this work also identifies a novel role for Claspin, an important Chk1 activator, in female fertility and cancer development, furthering our understanding of how dysfunction in the Claspin/Chk1 signaling pathway affects disease states. These findings improve our understanding of drug resistance in cancer therapy, which has important implications for clinical use of Chk1 inhibitors.This publication has 14 references indexed in Scilit:
- Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up‐regulationMolecular Oncology, 2020
- Rho GTPases modulate malignant transformation of tumor cellsSmall GTPases, 2014
- The role of RelA (p65) threonine 505 phosphorylation in the regulation of cell growth, survival, and migrationMolecular Biology of the Cell, 2011
- Chromosomal Instability Confers Intrinsic Multidrug ResistanceCancer Research, 2011
- IKK and NF-κB-mediated regulation of Claspin impacts on ATR checkpoint functionThe EMBO Journal, 2010
- Chromosomal alterations cause the high rates and wide ranges of drug resistance in cancer cellsCancer Genetics and Cytogenetics, 2005
- Regulation of NF-κB and p53 through activation of ATR and Chk1 by the ARF tumour suppressorThe EMBO Journal, 2005
- Human Claspin Is Required for Replication Checkpoint ControlJournal of Biological Chemistry, 2003
- Claspin, a Novel Protein Required for the Activation of Chk1 during a DNA Replication Checkpoint Response in Xenopus Egg ExtractsMolecular Cell, 2000
- The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells.The Journal of Experimental Medicine, 1988